Celldex Therapeutics (NASDAQ:CLDX) Shares Up 4.9% – What’s Next?

Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s share price was up 4.9% during trading on Tuesday . The company traded as high as $24.59 and last traded at $24.46. Approximately 187,152 shares were traded during mid-day trading, a decline of 79% from the average daily volume of 872,933 shares. The stock had previously closed at $23.31.

Analyst Upgrades and Downgrades

CLDX has been the topic of a number of research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a report on Monday, September 16th. The Goldman Sachs Group initiated coverage on shares of Celldex Therapeutics in a research note on Monday, September 30th. They set a “neutral” rating and a $45.00 price objective on the stock. Citigroup initiated coverage on shares of Celldex Therapeutics in a research note on Monday, October 7th. They set a “buy” rating and a $70.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research note on Thursday, November 7th. Finally, Wolfe Research cut shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Stock Performance

The company has a market capitalization of $1.66 billion, a price-to-earnings ratio of -9.88 and a beta of 1.60. The stock’s fifty day simple moving average is $31.51 and its two-hundred day simple moving average is $35.27.

Insider Activity

In other news, CEO Anthony S. Marucci purchased 11,500 shares of Celldex Therapeutics stock in a transaction that occurred on Monday, November 11th. The stock was acquired at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the transaction, the chief executive officer now owns 40,284 shares in the company, valued at $1,080,416.88. The trade was a 39.95 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 3.80% of the company’s stock.

Institutional Trading of Celldex Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CLDX. Price T Rowe Associates Inc. MD lifted its stake in Celldex Therapeutics by 631.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock worth $129,571,000 after acquiring an additional 2,664,915 shares in the last quarter. Wellington Management Group LLP lifted its position in Celldex Therapeutics by 14.5% in the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company’s stock worth $314,190,000 after buying an additional 1,167,659 shares in the last quarter. Novo Holdings A S acquired a new stake in shares of Celldex Therapeutics during the 2nd quarter valued at about $31,458,000. Point72 Asset Management L.P. grew its stake in shares of Celldex Therapeutics by 51.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock valued at $71,725,000 after buying an additional 654,194 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Celldex Therapeutics by 19.8% in the first quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company’s stock valued at $153,215,000 after acquiring an additional 604,251 shares during the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.